Michael Gelband’s Anavex Life Sciences AVXL Stock Holding History

Michael Gelband’s Portfolio AVXL Stock Details AVXL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-20,000	Closed	-$172K	–	1464
2025 Q1	$172K	Buy	+20,000	New	+$189K	﹤0.01%	1314
2024 Q4	–	Sell	-127,270	Closed	-$723K	–	1521
2024 Q3	$723K	Buy	+127,270	New	+$734K	﹤0.01%	1073
2023 Q4	–	Sell	-10,131	Closed	-$66K	–	1469
2023 Q3	$66K	Sell	10,131 -65,898	-87%	-$525K	﹤0.01%	1605
2023 Q2	$618K	Sell	76,029 -20,556	-21%	-$176K	0.01%	1281
2023 Q1	$828K	Sell	96,585 -40,532	-30%	-$405K	0.01%	1201
2022 Q4	$1.27M	Buy	137,117 +84,639	+161%	+$904K	0.02%	850
2022 Q3	$542K	Sell	52,478 -125,635	-71%	-$1.33M	0.01%	1343
2022 Q2	$1.78M	Buy	178,113 +152,189	+587%	+$1.44M	0.02%	830
2022 Q1	$319K	Buy	+25,924	New	+$319K	﹤0.01%	1733
2021 Q4	–	Sell	-35,342	Closed	-$634K	–	2154
2021 Q3	$634K	Buy	+35,342	New	+$703K	0.01%	1259
2021 Q2	–	Sell	-25,007	Closed	-$374K	–	2332
2021 Q1	$374K	Buy	+25,007	New	+$273K	0.01%	1534
2019 Q2	–	Sell	-16,200	Closed	-$49K	–	1095
2019 Q1	$49K	Buy	+16,200	New	+$38.7K	﹤0.01%	637

Other funds holding AVXL

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NWAM LLC Mercer Island, Washington $2B AUM 34.81% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Michael Gelband's AVXL Position: Q2 2025 in Review

Michael Gelband sold out of Anavex Life Sciences (AVXL) in Q2 2025, closing a stake of 20,000 shares — an estimated $172K sold.

Michael Gelband first reported a position in AVXL in Q1 2019 and held it in 12 quarters. The position peaked at $1.78M in Q2 2022. 178 funds tracked by Wall St. Rank hold AVXL as of Q2 2025.

Michael Gelband reported no remaining Anavex Life Sciences position as of Q2 2025 after selling out during the quarter.
Michael Gelband sold 20,000 Anavex Life Sciences shares in Q2 2025, an estimated $172K.
Michael Gelband first reported a position in Anavex Life Sciences in Q1 2019 and held it in 12 quarters.
Michael Gelband's Anavex Life Sciences position peaked at $1.78M in Q2 2022.
178 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2025.

Based on ExodusPoint Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.